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Abstract
Understanding the properties of viruses capable of establishing infection during perinatal
transmission of HIV-1 is critical for designing effective means of limiting transmission. We
previously demonstrated that the newly transmitted viruses (in infant) were more fit in growth, as
imparted by their envelope glycoproteins, than those in their corresponding mothers. Here, we further
characterized the viral envelope glycoproteins from six mother-infant transmission pairs and
determined whether any specific envelope functions correlate with HIV-1 subtype C perinatal
transmission. We found that most newly transmitted viruses were less susceptible to neutralization
by their maternal plasma compared to contemporaneous maternal viruses. However, the newly
transmitted variants were sensitive to neutralization by pooled heterologous plasma but in general
were resistant to IgG1 b12. Neither Env processing nor incorporation efficiency was predictive of
viral transmissibility. These findings provide further insight into the characteristics of perinatally
transmissible HIV-1 and may have implications for intervention approaches.
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Introduction
Mother-to-child transmission (MTCT) of HIV-1 is the primary mode of pediatric HIV-1
infection and remains a significant problem in developing countries where anti-retroviral
therapy (ART) is still not widely available. HIV-1 infected children account for 20% of all
HIV-1 related deaths (Luzuriaga and Sullivan, 2002). More than two thirds of new HIV-1
infections occur in sub-Saharan Africa and 60% of these infections are with HIV-1 subtype C
with a significant number of infections in infants and children. HIV-1 subtype C is currently
*Corresponding author: Nebraska Center for Virology, School of Biological Sciences, University of Nebraska-Lincoln, Morrison Center
P.O. Box 830666, Lincoln, NE 68583- 0900, Phone: (402) 472-4550; Fax: (402) 472-3323; cwood@unlnotes.unl.edu.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting
proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could
affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Virology. Author manuscript; available in PMC 2011 May 10.
Published in final edited form as:
Virology. 2010 May 10; 400(2): 164–174. doi:10.1016/j.virol.2009.12.019.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
responsible for the vast majority of new HIV-1 infections worldwide
(http://www.unaids.org). However, factors that contribute to the continuing expansion of
subtype C viruses have yet to be clearly elucidated.
It has been shown that subtype C viruses display biological properties, such as restricted CCR5
usage and reduced replicative capacity that distinguish it from other subtypes (Abebe et al.,
1999; Abraha et al., 2009; Ball et al., 2003; Bjorndal et al., 1999; Neilson et al., 1999; Zhang
et al., 2006). Such differences may contribute to the rapid spread and predominance of subtype
C HIV-1 in sub-Saharan Africa (Abraha et al., 2009; Ndung’u, Renjifo, and Essex, 2001). Since
many of these parameters are influenced by the HIV-1 envelope (Env) glycoprotein, we and
others have suggested that subtype C viruses might have Env glycoproteins that are atypical
in structure or function compared to viruses from other HIV-1 subtypes (Cilliers et al., 2003;
Zhang et al., 2006). Whether the observed differences in cellular tropism, transmission and
pathogenetic outcome between subtype C and other subtypes correlate with biological or
genetic properties of the Env glycoprotein has not been resolved. Previous studies of HIV-1
transmission, including sexual transmission and MTCT, have mainly focused on evaluating
the genotypic and antigenic properties of transmitted variants but have provided little
information on potential correlations between Env function and MTCT (Derdeyn et al.,
2004; Dickover et al., 2006; Haaland et al., 2009; Kliks et al., 1994; Rainwater et al., 2007;
Scarlatti et al., 1993a; Wolinsky et al., 1992; Wu et al., 2006). In addition, our understanding
of perinatal transmission in infants is mainly derived from studies of subtype B or other non-
subtype C HIV-1. The applicability of such findings to subtype C remains to be substantiated.
Given the high prevalence of subtype C infections, a complete understanding of virus
transmission and identification of factors that may affect the transmission of subtype C HIV-1
are of importance.
Selective transmission of a few maternal variants has been the dominant feature during MTCT
(Ahmad et al., 1995; Dickover et al., 2001; Scarlatti et al., 1993b; Wolinsky et al., 1992; Zhang
et al., 2002). However, the basis of the observed genetic bottleneck remains poorly defined
and the factors governing variant selection are largely unknown. The bottleneck transmission
has been attributed to various factors including specific viral selection (Wolinsky et al.,
1992) and neutralization resistance of the transmitted viruses (Dickover et al., 2006; Kliks et
al., 1994; Scarlatti et al., 1993a; Wu et al., 2006). Recently, we demonstrated that in infected
mother-infant pairs (MIPs), the newly transmitted viruses, those in infants, were selected to
have higher ex vivo fitness, as imparted by their envelope glycoproteins, than viruses from their
corresponding chronically infected maternal donors. Our study showed that the Env V1-V5
region was sufficient to confer the higher replicative fitness phenotype (Kong et al., 2008).
Genetic analyses indicated a significant viral bottleneck during perinatal transmission among
the MIPs analyzed (Zhang et al., submitted for publication). Since all the mother and infants
are anti-retroviral naïve, these MIPs provide a setting in which to examine the biological
properties of transmitted viruses and investigate the correlates of subtype C HIV-1 perinatal
transmission without additional selective pressure. Here, we further explored the relationships
between Env biological functions such as synthesis and processing, incorporation, or
susceptibility to antibody neutralization and the likelihood to achieve transmission through the
maternal-infant bottleneck. We found that in the majority of cases, the newly transmitted
viruses from the infant were less susceptible to neutralization by their maternal plasma
compared with contemporaneous maternal viruses, but no correlation between Env processing
or incorporation efficiency and transmissibility was detected. These results, in conjunction
with our previous studies, suggest that viruses with the higher replication fitness, and lower
susceptibility to neutralization by the maternal plasma were selectively transmitted during
subtype C HIV-1 perinatal transmission. These findings provide further insight into the
characteristics of perinatally transmissible HIV-1 and also provide important information
relevant to the development of effective vaccine intervention strategies.
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Materials and Methods
Patient information and sample collection
Six MIPs labeled 2617, 1449, 1084, 2669, 2873, 1984 from our previous study (Zhang et al.,
2006) were characterized in the study. The mothers were known to be HIV-1 positive at the
time of delivery and all subjects were asymptomatic and were not yet eligible for ART at the
time. The babies were all breast-fed and drug naïve. Maternal samples at delivery were defined
as baseline and infant baseline samples were referred to the first postpartum HIV-1 PCR
positive time point. The baseline HIV-1 serological status of the mother and HIV-1 infection
in infants was determined as previously described (Zhang et al., 2006).
Cell cultures
293T, COS-1 and TZM-bl ( NIH AIDS Research and Reference Reagent Program catalog no.
8129) cells were maintained in Dulbecco’s modified Eagle medium (DMEM) with 10% fetal
bovine serum (FBS, Hyclone) and 100 μg/ml penicillin-streptomycin. PBMC were purified
using Lymphoprep (Life Technology) from a HIV-seronegative donor and then propagated in
RPMI 1640 containing 10% FBS, 100 μg/ml penicillin-streptomycin and 5 μg/ml of
phytohemagglutinin (Sigma, St. Louis, MO) for 40 hrs before being infected with viruses.
Env glycoprotein expression constructs and proviral expression constructs
The V1-V5 region of env gene was amplified by nested PCR from uncultured patient PBMC,
cloned into the pGEM-T Easy vector and sequenced as described previously (Zhang et al.,
2006). The preexisting, genetically characterized Env V1-V5 clones were used as the source
of genetic materials for generation of the Env chimeras. Approximately 20 representative Env
clones, based on Env V1-V5 length and putative N-glycan number, as well as sequence
diversity, were selected from each MIP baseline viral population (Kong et al., 2008). The Env
V1-V5 region from selected clones was amplified from the pGEM-T Easy vector by using
primers containing restriction enzyme sites Dra III and AvrII: sense primer C-DraIII (5′-
TGACCCCACTCTGTGTCACTTTA-3′) and antisense primer C-AvrII (5′-
CTATTCCTAGGGGCTTAATTTCTACCACTT-3′). The resulting PCR products were
subcloned into a shuttle vector, pSP72 NLA/S/Av, using the restriction enzyme sites Dra III
and AvrII. The pSP72 NLA/S/Av was generated by introducing the envelope gene of pNL4-3
modified with AgeI/SbfI/AvrII by silent mutation into a cloning vector, pSP72 (Promega) and
was used for the sequential cloning of patient V1-V5 region of env gene into an Env expression
vector, pSRH NL A/S/Av. This vector was generated by modifying the mammalian expression
vector pSRH which contains an SV40 promoter and reading frames for NL 4-3 Tat, Rev and
Env (kindly provided by Dr. Eric Hunter, Emory University). The chimeric Env expression
construct containing patient-derived Env V1-V5 region was generated by substituting EcoRI
- XhoI region of pSP72A/S/Av with the corresponding region of pSRH NL A/S/Av. All the
patient-derived chimeric Env expression constructs were first screened for biological function
using the fusion assay. Briefly, 2 ×104 COS-1 cells per well grown in 24-well plates were
transfected with 0.5 μg of the patient-derived Env glycoprotein expression plasmid. Twenty-
four hours subsequent to transfection, 5 × 104 of the TZMbl (target) cells were added onto the
Env expressing COS-1 (effector) cells. The effector and target cells were allowed to fuse for
24 hours. The cells were stained for β galactosidase expression and the fusion level was
determined by the number of blue foci. Between 30% – 70% of the selected clones were
biologically functional. Finally, the functional envelope construct was transferred into a
proviral expression vector- pNL4-3 A/S/Av, with NL4-3 viral backbone, by substituting EcoRI
- XhoI region of pSRH NL A/S/Av with the corresponding region of pNL4-3 A/S/Av, resulting
in the infectious molecular clone plasmids. Between 4-13 representative Env clones from each
MIP baseline viral population were available for the functional assays as described below.
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Virus stocks
NL4-3 or chimeric viruses bearing patient-derived Env V1-V5 region were produced by
transfection of 293 T cells with proviral constructs. Nine μg of proviral construct was
transfected into 2.2 × 106 293 T cells using Fugene 6 (Roche). The resulting infectious viruses
were harvested 48 hrs post-transfection, filtered through 0.45μm filter and stored at −80°C.
The tissue culture dose for 50% infectivity (TCID50) was determined for each recombinant
virus in TZM-bl cells. Viral titer was defined as TCID50/ml.
Co-receptor usage and cell tropism
Co-receptor usage and cell tropism were defined using Ghost cell lines that express specific
co-receptors and MT-2 cells as described previously (Zhang et al., 2005).
Synthesis and processing of Env glycoproteins
The kinetics of glycoprotein synthesis and processing were analyzed by pulse-chase as
described previously (West et al., 2002) with some modifications. Briefly, 1.3 × 106 COS-1
cells grown in 10 cm culture dishes were transfected with 9 μg of each Env expression construct.
At 24 hrs post-transfection, cells were dissociated from the plate and divided into 6-well plates
at a density of 9 ×105 transfected cells per well to allow the cells to grow overnight. COS-1
cells expressing NL4-3 Env protein or chimeric Env proteins bearing patient-derived Env V1-
V5 region were starved for 40 min with DMEM Cys/Met-free medium and pulse-labeled with
[35S] Methionine for 45 min at 37°C. The pulse labeled cells were then chased in complete
medium for 2, 6 and 24 hrs, respectively. At the completion of the chase, the culture supernatant
was collected, filtered through a 0.45 μm syringe filter and lysed with lysis buffer to a final
concentration of 1% NP40, 0.1% SDS, 0.5% deoxycholic acid sodium salt and 10 μl/ml Halt
Protease Inhibitor Cocktail (Pierce). To prepare cell lysates, cells were washed twice with ice-
cold phosphate-buffered saline (PBS) and lysed in the buffer described above on ice. The cell
lysates were clarified by centrifugation at 20,000 × g for 1 min. The clarified cell lysates and
supernatants were immunoprecipitated with pooled subtype C HIV-1 infected patient serum.
Viral proteins were resolved on 8% SDS-PAGE and visualized by autoradiography.
Glycoprotein incorporation into virions
To determine the level of viral envelope glycoprotein incorporated into virus particles, 293T
cells were transfected with the proviral constructs. Briefly, 2.2 × 106 293T cells grown in 10
cm culture dishes were transfected with 9 μg of each proviral construct. At 48 hrs post-
transfection, viral supernatants were harvested and filtered through 0.45 μm filters. A fraction
was kept for p24 quantification and infectivity assay, and the remaining virus-containing
supernatant was centrifuged to pellet the virus at 65,000 rpm (Beckman, Type 90 Ti) through
a 20% (wt/wt) sucrose cushion for 2 hrs at 4°C. The resulting pellet was lysed for SDS-PAGE
analysis. Viral proteins were separated by SDS-PAGE, blotted onto PVDF membranes
(Amersham Biosciences) and analyzed by Western blotting using monoclonal antibody (mAb)
2F5 (Polymun Scientific Inc, Vienna, Austria) to detect gp41, or anti-p24 mAb (NIH AIDS
Research & Reference Reagent Program, Cat. no. 1513) to detect p24. Protein quantification
was performed using a Fluor-S™ Multilmager (BIORAD).
Viral infectivity assay
The p24 content of each virus stock from transfected 293T cells was determined using HIV-1
p24 ELISA kit (PerkinElmer Life Sciences, Inc.). Two ng of p24 of each virus was used to
infect 2 ×104 TZM-bl target cells in triplicates in the presence of 40 μg/ml of DEAE-dextran
in a 96-well plate. At 48 hrs post-infection, cells were lysed and luciferase activity was
measured using the Luciferase Assay System (Promega, Madison, WI). Luciferase activity was
measured using a LUMIstar Luminometer (BMG Lab technologies Offenburg, Germany).
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Background luminescence in uninfected wells was subtracted from all experimental wells.
Relative infectivity was calculated by comparing the luciferase activity between the patient’s
proviral construct and the NL4-3 transfected cells.
Replication kinetics of chimeric viruses
For replication kinetics in TZM-bl cells, equivalent infectious units, 200 TCID50, of each
chimeric viruses from transfected 293T cells were added to duplicate wells in a 48-well plate
containing 2 ×104 TZM-bl cells per well. After incubation at 37°C overnight, cells were washed
3 times with medium and 500 μl of fresh medium was added. A 250 μl aliquot of each infected
culture was sampled on day 0, 2, 4, 6, 8, 10, 12 and 14 and the culture was replenished with
an equal volume of fresh medium. In order to determine viral yield at each timepoint, 75 μl of
each collected culture supernatant was used to infect 2 ×104 TZM-bl cells in a 96- well plate.
At 48 hrs post-infection, cells were lysed and luciferase activity was determined as described
above.
Neutralization assays
The susceptibility of the chimeric viruses bearing patient- derived Env V1-V5 region to
neutralization by maternal or pooled plasma or mAb IgG1 b12 (Polymun Scientific Inc, Vienna,
Austria) was assayed in the TZM-bl cells in 96-well plates as described previously (Montefiori,
2004; Zhang et al., 2005) with some modifications. Briefly, 20 TCID50 of each provirus (in 50
μl) was incubated with equal volumes of threefold serial dilutions of IgG1 b12 or heat-
inactivated plasma, or with growth medium alone at 37°C for 1 hr in the presence of 1 μM
Indinavir and 40 μg/ml of DEAE-dextran. The virus-plasma or virus-antibody mixture was
then added to TZM-bl cells in triplicate for an additional 3 hr at 37°C. Thereafter, 50 ul of
medium was added to each well, and the cells were incubated at 37°C for 2 days. After two
days, the cells were washed once with PBS, lysed and the luciferase activity of each well was
measured as described above. Background luminescence in uninfected wells was subtracted
from all experimental wells. Differences between the luciferase activity in the presence of
plasma or antibody and growth medium alone were calculated as the percentage of antibody
neutralization. The IC50 was defined as the reciprocal dilution of plasma or the concentration
of the IgG1 b12 that causes 50% inhibition of virus infection and was calculated using
GraphPad Prism software version 5.0 (GraphPad Software, Inc., San Diego, CA). Maternal
plasma and pooled plasma from 50 HIV-1 subtype C infected Zambian patients were tested at
a starting dilution of 1: 50 and 1:100, respectively. The mAb IgG1 b12 was tested at a starting
concentration of 25 μg/ml.
Statistical analysis
All statistical tests were performed with GraphPad Prism software version 5.0. In cases in
which the IC50 for maternal plasma was < 50, the midpoint value between 0 and 50, 25, was
assigned for statistical analysis. For mAb IgG1 b12, the IC50 value of 25 was used when there
was < 50% neutralization at the highest concentration (25 μg/ml) tested, Significance was
reported when P ≤ 0.05, and a trend was reported when 0.05 < P ≤ 0.1. Correlation of
neutralization IC50 to the Env V1-V5 length and N-glycosylation sites was examined with
Spearman’s correlation test.
Results
HIV-1 infected mother-infant pairs
The genetically characterized HIV-1 subtype C Env sequences from six pre-existing mother-
infant pairs – MIP 2617, 1449, 1084, 2669, 2873 and 1984 (Zhang et al., 2006) were used as
source materials for generation of Env chimeras. These infants were all negative at birth for
Zhang et al. Page 5
Virology. Author manuscript; available in PMC 2011 May 10.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
HIV-1 by both viral isolation and PCR, but were found to be HIV-1 positive at either 2 months
(2617, 1449, 2669 and 2873) or 4 months (1084 and 1984) after birth. Thus, HIV-1 transmission
most likely occurred either during delivery or through breastfeeding. Because the amount of
sample from these children was limited, priority was given to viral isolation in lieu of PCR
when necessary (e.g., infant 1084, viral isolation was positive by 4 month but the first PCR
was performed 6 months after birth). The first PCR positive time point from each infant is
indicated in Table 1 along with the time points studied and the number of clones analyzed for
each patient.
Co-receptor usage and cell tropism of patient-derived viruses
Previously, we demonstrated that the primary viral isolates from these patients studied here
exclusively used CCR5 as co-receptor, exhibited macrophage-tropism, and did not infect T
cell lines or form syncytia in vitro (Zhang et al., 2006). To ensure that the characterized Env
sequences possessed co-receptor usage properties consistent with those defined for cognate
viruses isolated by co-culture, we generated infectious molecular clones in HIV-1 NL4-3
bearing patient-derived Env V1-V5 region. Co-receptor usage of the chimeric infectious
molecular clones was tested in Ghost cell lines expressing different co-receptors. Consistent
with what we observed for the primary isolates, all chimeric viruses exhibited CCR5 tropism
and did not form syncytia with the MT-2 cells (data not shown).
Biosynthesis and processing of patient-derived Env glycoprotein
The HIV-1 Env glycoprotein is synthesized as a 160-kDa precursor protein, gp160, that is
cleaved by cellular proteases during trafficking to the plasma membrane to generate the mature
surface glycoprotein gp120 and the transmembrane glycoprotein gp41. Thus the efficiency of
glycoprotein synthesis and cleavage could impact glycoprotein availability for incorporation
into particles, and therefore the infectivity of those particles. The kinetics of synthesis and
processing of patient-derived Env glycoproteins was analyzed in COS-1 cells by pulse-chase
analysis. The results of two representative pairs are shown in Figure 1 and the rest are shown
in Supplementary Figure 1. The glycoprotein from maternal and infant variants was
synthesized and processed over the course of a 24 hr chase, as evidenced by the decay of labeled
gp160 concomitant with the increase of gp120 and gp41 in the cell lysates (Fig. 1A and
Supplementary Fig. 1A). However, only a small fraction of the precursor gp160 was processed
into the mature gp120. The amount of gp120 detected in the supernatants increased over the
chase period indicating shedding from the plasma membrane after glycoprotein processing
(Fig. 1B and Supplementary Fig. 1B). As early as at 2 hrs of chase, the gp120 and gp41 appeared
in cell lysates, and gp120 was observed in supernatants derived from all the Env expression
clones (Fig. 1A and B; Supplementary Fig. 1A and B). Slight differences in electrophoretic
mobility of gp120, which could be attributed to differences in the extent of N-glycosylation,
were observed for different chimeras in both cell lysates and supernatants (Fig. 1A and B;
Supplementary Fig. 1A and B). Nevertheless, no obvious pattern in Env synthesis and
processing that could distinguish the transmitted (infant) from non-transmitted (mother)
viruses, despite differences in the level of expression and extent of processing among chimeras.
Infectivity of maternal and infant chimeric viruses
In order to evaluate the ability of each Env glycoprotein to mediate viral infectivity, we
generated patient Env V1-V5 region-bearing viruses by transfection of 293T cells. The
resulting virus-containing supernatants were normalized for p24 content and were used to infect
TZM-bl indicator cells. Differential infectivity phenotypes were observed among transmitted
and non-transmitted viruses (Fig. 2). For most patient-derived chimeras, with the exception of
MIP 2669, the viral infectivity was either slightly lower (MIP 1449 and 2617 Env) or higher
(MIP 1084 and 2617) relative to NL4-3 having wild type Env. There were also some patient-
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derived viruses that exhibited much lower infectivity (1084 i6m-3 and 2669M0-3) or almost
no detectable infectivity (2617 i2m-3) when compared to the NL4-3. These differences in
infectivity did not always parallel their fusion capacity, since higher Env-mediated fusogenicity
did not always link to efficient viral infectivity (data not shown). Importantly, the differential
level of viral infectivity observed among mother and infant viruses did not segregate the
transmitted from non-transmitted viruses, suggesting a lack of correlation between the viral
infectivity and transmissibility.
Replication kinetics of maternal and infant chimeric viruses
The ability of the chimeric viruses derived from each mother-infant pair to establish a
productive infection in TZM-bl cells was compared (Fig. 3). Equivalent infectious units of
each chimeric virus were used to infect the cells, and replication levels were determined by
measuring the luciferase activity from the infected TZM-bl cells. NL4-3 which was used as
control replicated to a higher level relative to most patient-derived chimeric viruses. It also
displayed a steady increase in the replication for the duration of the experiment in TZM-bl cells
(Fig. 3A, B, C, and D). There were also a few patient-derived viruses that replicated as well
as NL4-3 (MIP 2617 M0-3, i2m-4 and 2669 M0-2 and i2m-3). In addition, there were some
maternal and infant viruses that were unable to establish a productive infection in TZM-bl cells
such as 1084 i6m-3, 2671 i2m-3 and 2669 M0-3. In general, the replication kinetics was
variable between different patient isolates and within the MIPs with no distinct patterns being
observed except that most patient Env chimera viruses replicated less well than the subtype B
NL4-3.
Incorporation of viral Env into viral particles
Our investigation of Env synthesis and processing analyses revealed no correlations with
transmission, but glycoprotein processing is not always coupled to effective incorporation or
function (Dubay et al., 1995). To investigate whether the level of Env incorporation into virions
contributed to differences in infectivity or correlated with transmission, we used monoclonal
antibody 2F5 to detect the quantity of gp41 incorporated into virions. We chose to quantify
Env incorporation using gp41 detection since a specific and sensitive anti-subtype C gp120
antibody was not available and all chimeras share a common gp41 sequence derived from
NL4-3. Densitometry analyses of the blots indicated that different levels of gp41 were
incorporated into chimeric viral particles from the MIPs, as calculated from gp41/p24 ratio
(Fig. 4). For example, with 2617 i2m-3 and 2669 M0-3, where poor Env incorporation was
observed (Fig. 4C and D), the virions also exhibited low infectivity and replication deficits
resulted (Fig. 2C and D and Fig. 3C and D). For most chimeric viruses, particularly for MIP
2617 such as M0-2, 3, 5 and i2m-2, higher levels of Env in the virions correlated with greater
infectivity (Fig. 4 and Fig. 2). However, the differential infectivity cannot be simply explained
by the levels of envelope incorporated and is likely also due to differences in inherent infectivity
potency, as observed with 1084 i6m-3 and 2669 i2m-4, where poor infection or replication
kinetics were observed although substantial levels of Env were incorporated into the particles
(Fig. 2A and D; Fig. 3A and D; Fig. 4A and D). For others, only a small fraction of the Env
incorporated into the HIV-1 particles was sufficient for infection. This can be seen with 1084
M0-3, 1084 i6m-2 and 1449 M0-2 (Fig. 4A and B; Fig. 2A and B). Despite variability in
incorporation of Env into the virions, no identifiable pattern in the level of Env incorporation
segregated maternal from infant chimeras.
Sensitivity of maternal and infant envelope variants to neutralization by maternal plasma
One of the primary selective pressure acting on Env is neutralizing antibodies (nAbs). MTCT
is unique in that it occurs in the presence of passively acquired maternal antibody before birth.
This passive transfer of maternal antibodies to infants could play a role in the selection of
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transmitted viruses with an nAb escaped phenotype. Therefore, we determined the sensitivity
of mother/infant Env-chimera viruses to neutralization with maternal baseline plasma collected
at delivery. A total of 49 functional Env chimeras were tested for their sensitivity to
neutralization by maternal baseline plasma. Among the 6 MIPs tested, the maternal variants
of 1984, 1084, 2873, 1449 and 2669 were generally sensitive to the maternal plasma; infant
viruses, in contrast, were more neutralization-resistant, as indicated by their lower median
inhibitory concentrations (IC50) (Fig. 5A). Among the infants tested, infant 2669 harbored
relative sensitive variants with higher IC50 compared to those of other infant variants. For MIP
2617, both mother and infant variants displayed very low or undetectable neutralization by the
maternal plasma, although it is possible that this is due to the lack of effective neutralization
response in the mother (Fig. 5A). When the six pairs were considered in aggregate, the IC 50
value of variants from the infants (median 77) was significantly lower than that from the
mothers’ (median 406; P = 0.03; Mann Whitney test), indicating that the transmitted variants
were more resistant than the mother’s virus population to maternal time-of-delivery plasma
(Fig. 5B). Taken together, our results indicate that neutralization resistant subtype C HIV-1
variants have a higher probability of achieving perinatal transmission, even though variants
which are susceptible to nAbs could also be transmitted.
Sensitivity of maternal and infant envelope variants to neutralization by heterologous
antisera
We further assessed the neutralization sensitivity of the MIP viruses using a pooled subtype C
HIV-1 infected patient serum to determine if they differed in their sensitivity to neutralization
by heterologous antibodies. Comparisons of neutralization sensitivity to pooled HIV-1 plasma
indicated that the pooled heterologous plasma was very effective in neutralizing the variants
from both mother (median IC50, 1089) and infant (median IC50, 832), suggesting that none of
the infant variants were inherently resistant to neutralization. However, the neutralization
profile varied among different pairs (Fig. 6A). Some maternal viruses showed higher
susceptibility to the heterologous pooled plasma than did their infant variants (MIPs 1984,
2873 and 2669); while some infant viruses were tended to be more susceptible than those in
their corresponding mothers (MIP 1084), or viruses from both mother and infant were
comparable in their neutralization sensitivity (MIPs 1449 and 2617) (Fig. 6A). Notably, for
MIP 2617, all the mother and infant variants were neutralized by pooled plasma, although they
all showed very poor neutralization when tested with the maternal plasma, indicating that
neutralization resistance is not an intrinsic property of these viruses (Fig. 6A). However,
statistical analysis of all the viral variants indicated that there were no significant differences
in the sensitivity of the mother and infant variants to neutralization by pooled heterologous
plasma although there was a trend toward the infant variants being more resistant to the
neutralization by the pooled plasma than the maternal variants (Fig. 6B, P = 0.07; Mann
Whitney test). Moreover, for most cases, the pooled plasma neutralized the variants from
mother and infant more efficiently than the maternal plasma, indicating high potency and broad
specificity of this plasma pool.
Susceptibility of maternal and infant envelope variants to neutralization by monoclonal
antibody
We also evaluated the susceptibility of the maternal and infant Env-chimera viruses to the
monoclonal antibody, IgG1 b12, derived from a subtype B infected individual, and which
recognizes an epitope overlapping the CD4-binding site (Burton et al., 1991; Burton et al.,
1994; Roben et al., 1994) and was shown to be somewhat effective against the subtype C Env
surface subunit as compared to other broadly neutralizing monoclonal antibodies (Binley et
al., 2004; Bures et al., 2002; Gray et al., 2006; Kulkarni et al., 2009; Li et al., 2006). Our results
indicated that there was a wide range of sensitivity of our subtype C viruses to IgG1 b12. The
majority of our panel of viruses (30 of the 49, 61%) were resistant to b12 demonstrating less
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than 50% neutralization at concentrations up to 25 μg/ml. The most resistant viruses were those
from MIPs 2617, 2873 and 2669 (Table 2). The IgG1 b12 neutralized 7 of the 24 infant variants
tested, with IC50 ranging from 0.6 to 25 μg/ml; whereas 12 of the 25 maternal variants were
neutralized and had IC50 ranging from 0.06 to 25 μg/ml with this mAb (Table 2). In addition,
the inter-pair differences in susceptibility to IgG1 b12 were also evident. Notably, for MIP
1984, all the maternal viruses were more sensitive to neutralization by b12 compared to the
infant viruses, with IC50 values ranging from 0.06 to 0.6 μg/ml for the maternal viruses whereas
4.3 to > 25 μg/ml for the newly transmitted viruses (Table 2). This is consistent with the
observations with autologous and heterologous pooled plasma for this pair. Similarly, the
transmitted viruses (IC50 value of 22 to >25 μg/ml) from MIP 1084 were generally less sensitive
to IgG1 b12 than the maternal variants (IC50 value of 5.3-7.3 μg/ml) although two exceptions
(1084M0-1 and M0-4) were identified among the nontransmitted viruses. The latter two
maternal viruses were also more resistant to autologous plasma compared to the rest of the
maternal variants. In contrast, variants derived from infant 1449 showed higher susceptibility
to this mAb than did the mother variants (Table 2), which is different from the results with
autologous plasma. When all the variants from 6 pairs were considered together, there was a
marginally significant difference in the susceptibility to IgG1 b12 between the maternal and
infant variants, with the infant viruses being more resistant than those of the mothers (P = 0.04;
Mann Whitney test). However, this difference could be largely due to MIP 1984, where the
mother variants were particularly sensitive (Table 2).
Correlation between neutralization sensitivity and Env genetic characteristics
Our genetic analysis indicated that infant Env V1-V5 sequences from five of the six MIPs have
lower mean number of N-linked glycosylation sites (PNGS) than those of their mothers,
suggesting that viruses harboring Env glycoproteins with fewer potential N-glycan could be
selected during the transmission among these MIPs (Zhang et al., submitted for publication).
In addition, in this study, we observed that neutralization resistant variants are dominant among
transmitted viruses. We, therefore, further evaluated the relationship between neutralization
sensitivity and the Env genetic features, such as the length polymorphisms and the number of
PNGS in Env. Aggregate analysis of the Env V1-V5 length from six MIPs revealed that the
acquisition of the Env V1-V5 length was not significantly associated with neutralization
susceptibility of these variants to either the maternal plasma or the pooled plasma (P = 0.59;
P = 0.13) (Fig. 7A and B). However, higher number of PNGS in this region was found to
correlate with greater neutralization sensitivity to the maternal plasma but not the pooled
plasma (P = 0.02; P = 0.20) (Fig. 7C and D).
Discussion
Understanding the properties of viruses capable of establishing infection during perinatal
transmission of HIV-1 is critical to guide the design of vaccines or therapeutics attempting to
block transmission. In this study, viral Env glycoproteins from six anti-retroviral naïve mother-
infant pairs were compared for their biological and immunologic properties to discern any
parameters that might correlate with MTCT. To our knowledge, this study represents the first
detailed analysis of maternal donor and recipient infant Env biological properties and
sensitivity to neutralization by autologous or heterologous antibodies in the context of HIV-1
subtype C perinatal transmission.
We have recently characterized the replicative fitness of these perinatally transmitted viruses
in dual infection competitions. Our results indicated that infant viruses possess a growth
advantage over those derived from their chronically infected mothers, and the advantage was
conferred by Env V1-V5 region (Kong et al., 2008). Higher fitness may thus enable the
transmitted virus to establish more efficient propagation at the site of infection in the new host.
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A number of factors could affect viral fitness and thereby transmission, including more efficient
processing and incorporation of the transmitted viral Env. In addition, the ability of the virus
to withstand immune selection pressures such as neutralizing antibodies may also affect the
transmissibility. We therefore tested whether transmitted viruses were also neutralization
resistant or whether a compromise between immune escape and replication robustness in the
new host occurs.
Our analysis of the Env processing or incorporation efficiency did not distinguish between
maternal (non-transmitted) and infant (transmitted) Env; therefore, the efficiency of Env
processing and incorporation do not seem to impact the likelihood of subtype C HIV-1 perinatal
transmission in our cohort. The slight differences in the Env’s electrophoretic mobility
observed in Env processing assay could indicate the extent of glycosylation among those
maternal and infant Env chimeras. Since glycosylation has a profound effect on the proper
folding, oligomerization and stability of glycoproteins, further studies will be needed to
investigate how the extent of glycosylation affect the biological function of the glycoproteins.
Moreover, our study also indicated that the viral replication kinetics did not differ between
mother and infant variants tested. This is in agreement with a non-subtype C HIV-1 MTCT,
where similar replication profiles of the mother and infant isolates were observed (Kliks et al.,
1994). However, our co-infection growth competition assay of these MIPs indicated that the
transmitted viruses are more fit than their mother’s (Kong et al., 2008), suggesting that
differences in viral fitness during transmission can only be differentiated by direct competition.
Indeed, this has been observed in an earlier study, where the differences in viral fitness
associated with escape from cytotoxic T lymphocytes between the wild type and mutant viruses
can only be detected by direct competition assay (Martinez-Picado et al., 2006).
Unlike other modes of transmission, MTCT occurs in the face of passively acquired maternal
antibody before birth. Thus, maternal neutralizing antibody could impose a selective pressure
on the transmitted virus. We, therefore, examined whether the maternal nAbs play a role in
selecting for the transmissible viruses. Our observations indicated that for most cases, the
transmitted viruses were less susceptible to neutralization by their baseline maternal plasma
than the contemporaneous maternal viruses. This is consistent with previous studies on subtype
A and B perinatal transmission (Dickover et al., 2006; Kliks et al., 1994; Wu et al., 2006).
Kliks et al. have found that five of the six infected infants tested harbored viruses which were
less susceptible to their mother’s sera (Kliks et al., 1994). More recently, it has been shown
that neutralization escape variants were favored during subtype A HIV-1 perinatal transmission
(Wu et al., 2006). Similarly, in a study of subtype B MTCT, where in five of the seven
transmitting mothers with autologous nAbs, the neutralizing antibody titer to the infant’s virus
was lower than that of the maternal isolates (Dickover et al., 2006). Our results indicated that
a preferential transmission of neutralizing antibody escape variants also occurred in the context
of subtype C HIV-1 MTCT, supporting the notion that maternal nAbs exert a preventive and
selective effect in perinatal transmission (Dickover et al., 2006; Kliks et al., 1994; Wu et al.,
2006). Among our study cohort, infants 2873 and 1449 are characterized as fast progressors
and died within the first year after birth; whereas infants 1084 and 1984 were diagnosed as
slow progressors. Our results indicated that sensitivity to neutralization of the infected infants
did not appear to correlate with disease progression since variants from these infants were, in
general, resistant to the neutralization by their maternal plasma. Collectively, our observations
and those of others suggest that neutralization insensitive variants are favored during HIV-1
perinatal transmission, but the transmission of neutralization sensitive variants can still occur
in spite of the presence of maternal neutralizing antibodies. In addition, our results also indicate
that resistance to maternal neutralizing antibodies is not predictive of disease progression in
the infected children.
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Understanding the role of nAbs, including heterologous nAbs, in MTCT is important for
determining whether passive administration of nAbs will be beneficial. Neutralization analyses
employing pooled HIV-1 plasma revealed a higher susceptibility of both maternal and infant
variants although the infant variants appeared to be less susceptible than the maternal variants,
indicating that heterologous neutralization can be relatively potent. The relatively higher
susceptibility of infant viruses to neutralization by pooled HIV-1 plasma compared to maternal
plasma indicated that no newly transmitted variants were inherently resistant to HIV-1 antibody
neutralization. This finding is in agreement with a previous study on subtype A HIV-1 perinatal
transmission (Wu et al., 2006). In addition, our observation supports the proposed combined
vaccine/passive monoclonal antibody strategy for prevention of HIV-1 transmission by breast
feeding (Dickover et al., 2006).
Our data with IgG1 b12 showed that only 39% (19/49) viruses bearing the maternal or infant
Env could be neutralized by IgG1 b12. This is similar to a recent study on subtype C HIV-1
from India, where only 20% of the studied viruses were neutralized by b12 (Kulkarni et al.,
2009). However, these results are somewhat different from those of several previous studies
on HIV-1 subtype C with relative smaller cohorts, where the IgG1 b12 could neutralized 57–
67% of the viruses tested (Binley et al., 2004; Gray et al., 2006; Li et al., 2006). More
importantly, our findings indicated that as a group, the newly transmitted viruses were likely
to be more resistant than their maternal variants to this mAb although for some pairs both
maternal and infant variants showed similar resistance to this mAb. This suggests that there
could be a selection for altered IgG1 b12 epitope exposure during the transmission. Viruses
harboring Env with under-represented IgG1 b12 epitopes appeared to be favored during HIV-1
subtype C perinatal transmission. The relative insensitivity of the newly transmitted viruses to
this mAb implies that IgG1 b12 may have limited benefit in preventing HIV-1 subtype C
MTCT. This is supported by a previous subtype C paediatric study with a relative small sample
size from South Africa (Gray et al., 2006). Our data, as well as those of others, underscore the
importance of evaluating newly transmitted variants in endemic areas when designing
neutralizing Ab-based vaccine immunogens.
Our results of selective perinatal HIV-1 transmission of nAbs escape variants differs from
heterosexual transmission of subtype C HIV-1 in discordant couples, where viruses with
shorter Env V1-V4, and fewer glycans are more susceptible to neutralizing antibodies, but
mediate more efficient heterosexual transmission (Derdeyn et al., 2004). These patterns,
however, have not been confirmed in subtype B sexual transmission (Chohan et al., 2005;
Frost et al., 2005a; Frost et al., 2005b), but viruses with shorter V1-V2 length and reduced
sequons have been reported in a subtype A heterosexual transmission study (Chohan et al.,
2005). The discrepancy in viral characteristics, including genotypic and phenotypic
parameters, leading to preferential transmission of particular Env variants between sexual and
perinatal transmission studies could be due to fundamental differences in the mode of
transmission or due to subtype-specific virological factors. For sexual transmission, the
mucosal barrier is likely to be a major constraint on the transmitting virus, while perinatal
transmission is also affected by the presence of passively transferred maternal neutralizing
antibodies (Derdeyn and Hunter, 2008; Haaland et al., 2009).
We also investigated the Env genetic characteristics associated with the neutralization profiles
of these variants. We found that acquisition of Env N- glycan of the mother and infant’s
sequences correlated with the enhanced neutralization susceptibility of these variants to the
maternal plasma. This was somewhat unexpected given that neutralization resistance is
generally linked to increased PNGS in viruses that evolve during chronic infection (Cheng-
Mayer et al., 1999; Wei et al., 2003). Therefore, it is likely that different mechanisms could be
involved in determining the neutralization phenotype of the virus in the cases of subtype C
perinatal transmission. Further studies will be needed to evaluate how the changes in Env N-
Zhang et al. Page 11
Virology. Author manuscript; available in PMC 2011 May 10.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
glycan affect the neutralization outcome of the viruses during perinatal transmission. Different
from a subtype A perinatal transmission study (Wu et al., 2006), where greater sensitivity to
maternal plasma neutralization was shown to correlate with shorter variable loops in Env
sequence, we did not observed any correlation between the Env length and neutralization
sensitivity in our cohort. However, acquisition of length in Env V1-V4 region of donor and
recipient’s sequences were linked to enhanced neutralization resistance to the autologous or
heterologous antibodies in the cases of subtype C HIV-1 heterosexual transmission (Rong et
al., 2007). Therefore, our results, together with those from others, highlight the need to further
explore genetic and immunologic correlates of different subtypes and different routes of
transmission.
In summary, our data, though limited in sample size, suggests that both viral and immunologic
factors, including Env glycosylation status (Zhang et al., submitted for publication), viral
replication fitness (Kong et al., 2008), and maternal nAbs play a role in subtype C HIV-1
perinatal transmission. Variants with the characteristics of higher replication fitness, resistance
to maternal nAbs and reduced glycosylation in Env were preferentially transmitted through the
maternal-infant bottleneck during subtype C HIV-1 transmission. In addition, the newly
transmitted variants were relatively sensitive to neutralization by pooled heterologous plasma
but most of them were resistant to IgG1 b12. Moreover, neither Env processing nor
incorporation efficiency was predictive of viral transmissibility. These findings provide further
insights for unraveling selective pressures that occur during HIV-1 perinatal transmission, and
may have implications for pediatric vaccine design and prevention of perinatal transmission.
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Figure 1. Synthesis and processing of Env glycoproteins gp160 and gp120 of two representative
MIPs 1084 and 2617
COS-1 cells expressing chimeric Env proteins bearing patient-derived Env V1-V5 region were
pulse-labeled with [35 S] methionine at 37°C for 40min. Cells were resuspended in complete
medium and chased for varying times as indicated (hr). Cell lysates and supernatant were
immunoprecipitated with pooled anti-HIV-1 antisera. Viral proteins from cell lysates (A) and
supernatant (B) were resolved by SDS-PAGE.
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Figure 2. Relative infectivity of chimeric viruses from representative pairs
Chimeric viruses bearing patient-derived Env V1-V5 region or NL4-3 were produced by
transfection of 293 T cells with the indicated proviral constructs and normalized to p24. Two
ng of p24 of each virus was used to infect TZM-bl target cells in triplicates in the presence of
40 μg/ml of DEAE-dextran as described in material and methods. After 48 hrs post-infection,
cells were lysed and luciferase activity was measured. The infectivity of NL 4-3 was set at 100,
the infectivity of patient-derived chimeric viruses was calculated relative to this value.
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Figure 3. Replication kinetics of chimeric viruses from representative pairs
Equal amount of infectious unit from each chimeric virus bearing patient-derived Env V1-V5
region was used to infect TZM-bl cells. NL4-3 was used as control. Cell-free supernatant was
collected and assayed for replication kinetics at indicated days post-infection. The level of viral
replication was determined by infection TZM-bl cells by viruses harvested from day 2, 4, 6,
8, 10, 12 and 14. After 48 hrs post-infection, cells were lysed and luciferase activity was
measured.
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Figure 4. Incorporation of patient-derived Env glycoprotein into infectious virions
293T cells were transfected with the indicated proviral expression constructs and the resulting
chimeric viruses bearing patient-derived Env V1-V5 region were collected at 48hrs post-
transfection. The viruses were pelleted through a 20% (wt/wt) sucrose cushion by
ultracentrifugation from the clarified supernatants and the viral proteins were analyzed by
Western blot. Gp41 protein was detected by anti-gp41 mAb 2F5, and p24 was detected by
using anti-p24 mAb. Bands corresponding to gp41 and p24 are indicated. Env incorporation
into virions was calculated as gp41/p24 ratio. For each pair, the NL4-3 value was set at 1, the
relative Env incorporation for each virus was calculated relative to this value. UN means that
the signal is undetectable.
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Figure 5. Neutralization sensitivity of envelope variants for maternal plasma
(A) Comparison of neutralization IC50 of maternal (○) and infant (Δ) variants bearing patient-
derived Env V1-V5 region for each transmission pair. The baseline maternal plasma was tested
at a starting dilution of 1: 50 as indicated by the dashed horizontal line. The luciferase activity
obtained for each virus in the absence of serum was set to 100 %, and the neutralization of the
test plasma was calculated relative to this value. The IC50 was defined as the dilution of plasma
that causes 50% inhibition of virus infection. The horizontal bars indicate the median IC50
value for each individual. (B) Comparison of IC50 between the mother (○) and infant (Δ)
variants. The P value of the comparison is shown. The horizontal bars indicate the median
IC50 value. The dashed horizontal line indicates the lowest dilution tested.
Zhang et al. Page 20
Virology. Author manuscript; available in PMC 2011 May 10.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 6. Neutralization sensitivity of envelope variants for pooled plasma
(A) Comparison of neutralization IC50 of maternal (○) and infant (Δ) variants bearing patient-
derived Env V1-V5 region for each transmission pair. A pooled HIV-1 plasma was tested at a
starting dilution of 1:100 as indicated by the dashed horizontal line. The IC50 from each
individual were calculated as in Fig. 5 and compared. The horizontal bars indicate the median
IC50 value for each individual. (B) Comparison of IC50 between the mother (○) and infant
(Δ) variants. The P value of the comparison is shown. The horizontal bars indicate the median
IC50 value. The dashed horizontal line shows the lowest dilution tested.
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Figure 7. Correlation between neutralization sensitivity and genetic characteristics of the envelope
Neutralization of maternal (○) and infant (Δ) variants was performed with either maternal
plasma (A and C) or pooled plasma (B and D). The IC50 was defined as the dilution of plasma
that causes 50% inhibition of virus infection. Amino acid lengths and PNGS in Env V1-V5
region of the mother and infant variants were calculated. The coefficient r and P values were
generated using Spearman’s correlation test.
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Table 2
IC50 values of IgG1 b12 with each maternal and infant variant
Patient ID Subject Clone ID IC50 (μg/ml)
1984 Mother 1, 2, 3, 4, 5, 6, 7 0.06–0.6
Infant 1 5.6
2, 6 >25
3, 5 25
4 4.3
1084 Mother 1, 4 >25
2 5.3
3 7.3
Infant 1 21.6
2, 3 >25
1449 Mother 2 2.2
3 >25
Infant 1 0.6
2 0.8
2617 Mother 1, 2, 3, 4 >25
5 25
Infant 1, 2, 3, 4 >25
2873 Mother 1, 3, 4 >25
2 1.5
Infant 1, 2, 3, 4 >25
2669 Mother 2, 3, 4 >25
Infant 1, 2, 3, 4, 5 >25
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